Valued at a market cap of $28 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical gadget firm that focuses on the design, growth, and commercialization of steady glucose monitoring (CGM) methods for the administration of diabetes and metabolic well being in america and internationally.
Corporations with a market cap of $10 billion or extra are sometimes known as “big-cap shares.” DXCM matches squarely into that class, with its market cap exceeding this threshold and reflecting its substantial measurement and affect within the medical gadgets business.
Extra Information from Barchart
Nevertheless, DXCM inventory is down 19.3% from its 52-week excessive of $89.98 touched on July, 30. Furthermore, DXCM declined marginally over the previous three months and has lagged behind the Dow Jones Industrial Common ($DOWI), which rose 5.8% throughout the identical interval.
Zooming out slightly additional, the state of affairs stays the identical. Over the previous 52 weeks, DXCM has declined 15.2%, underperforming DOWI’s 21.5% acquire.
DXCM has been buying and selling above its 200- and 50-day shifting averages since final month, indicating bullish momentum.
On Apr. 30, DXCM inventory rose 3.5% following the discharge of its Q1 2026 earnings. The corporate’s income for the quarter amounted to $1.2 billion and surpassed the Avenue’s estimates. Furthermore, its adjusted EPS for the interval got here in at $0.56, additionally topping Wall Avenue’s forecasts. DexCom expects full-year income within the vary of $5.16 billion to $5.25 billion.
When stacked towards its peer, GE HealthCare Applied sciences Inc. (GEHC), DXCM has underperformed. Over the previous yr, GEHC inventory has declined 10.3%.
Nevertheless, sentiment on DXCM stays extremely optimistic. Among the many 27 analysts masking the inventory, the consensus score is a “Sturdy Purchase.” Its imply worth goal of $81.58 suggests 12.4% upside from present ranges.
On the date of publication, Aritra Gangopadhyay didn’t have (both straight or not directly) positions in any of the securities talked about on this article. All info and knowledge on this article is solely for informational functions. This text was initially printed on Barchart.com
